Containing Polysaccharides (e.g., Sugars) Patents (Class 424/493)
-
Patent number: 8568785Abstract: Provided is a process for producing spherical base granules comprising a easily water-soluble drug and suited for film coating by spraying a layering liquid over pharmaceutically inert spherical core particles, thereby coating the particles with a layer comprising the easily water-soluble drug, wherein (1) the spherical core particles have a microcrystalline cellulose content of 30 mass % or greater and a water absorbing capacity of 0.5 cm3/g or greater; and (2) the layering liquid is an aqueous solution comprising at least the easily water-soluble drug and a low water-soluble saccharide.Type: GrantFiled: July 18, 2007Date of Patent: October 29, 2013Assignee: Asahi Kasei Chemicals CorporationInventors: Yoshihito Yaginuma, Rika Matsumoto
-
Patent number: 8568784Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.Type: GrantFiled: November 10, 2010Date of Patent: October 29, 2013Assignee: Morehouse School of MedicineInventors: James W. Lillard, Rajesh Singh, Shailesh Singh
-
Publication number: 20130280325Abstract: This invention relates to compressed solid oral dosage form able to contain a high load of active pharmaceutical ingredient, showing a controlled release profile, and consisting of individual particles wherein each individual particle comprises an active pharmaceutical ingredient and wherein each individual particle is coated with a layer comprising at least one plasticizer.Type: ApplicationFiled: December 22, 2011Publication date: October 24, 2013Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Luis Soler Ranzani, Albert Falivene Aldea, Ángel Santanach Delisau, Gemma Casadevall Pujals
-
Publication number: 20130273170Abstract: The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.Type: ApplicationFiled: April 11, 2012Publication date: October 17, 2013Inventor: Jay Hooper
-
Publication number: 20130266660Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: October 10, 2013Applicant: CIMA LABS Inc.Inventor: Ehab Hamed
-
Patent number: 8551501Abstract: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-? (IFN-?).Type: GrantFiled: August 21, 2008Date of Patent: October 8, 2013Assignee: Mucovax Inc.Inventor: Peter Strong
-
Patent number: 8545890Abstract: The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.Type: GrantFiled: November 14, 2008Date of Patent: October 1, 2013Assignee: Rubicon Research Private LimitedInventors: Pratibha Pilgaonkar, Maharukh Rustomjee, Anilkumar Gandhi, Pradnya M. Bagde
-
Patent number: 8541421Abstract: The present invention provides, in part, substituted thieno[2,3-d]pyrimidines and methods of contacting compositions with such compounds to enhance the sweet taste of said compositions.Type: GrantFiled: March 18, 2011Date of Patent: September 24, 2013Assignee: Senomyx Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Publication number: 20130243868Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.Type: ApplicationFiled: February 26, 2013Publication date: September 19, 2013Applicant: Avant Garde Therapeutics and Technologies LLCInventors: Leo RUBIN, Shaker Mousa
-
Publication number: 20130245357Abstract: The present invention provides derivatized magnetic nanoparticles, methods for making such nanoparticles, and methods for their use.Type: ApplicationFiled: February 7, 2011Publication date: September 19, 2013Applicant: SANFORD RESEARCH/USD, a nonprofit Corporation Organized Under South Dakota LawInventors: Subhash Chauhan, Meena Jaggi, Murali Mohan Yallapu
-
Publication number: 20130243867Abstract: Provided herein is a micelle composition comprising a polyethylene glycol (PEG), a DC-cholesterol, and a dioleoylphosphatidyl-ethanolamine (DOPE) and either or both a pharmaceutical compound core and a polynucleotide coating. Also provided herein is a method of administering one or more compounds to a cell comprising administering to the cell a micelle composition comprising 1) PEG-PE, a DC-cholesterol, and DOPE, and 2) the one or more compounds, wherein the compounds are selected from the group consisting of a polynucleotide and a pharmaceutical composition. Further provided are methods for detecting the micelle composition.Type: ApplicationFiled: February 22, 2013Publication date: September 19, 2013Applicant: University of South Florida (A Florida Non-Profit Corporation)Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Mark Christian Howell, Suraj Kishore Dixit, Chunyan Wang
-
Publication number: 20130236543Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Masanori ITO, Kenji EGUSA, Kyle KLEINBECK, Roman MESSERSCHMID, Peter SCHNEIDER, Venkata VOLETI
-
Patent number: 8529955Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: September 10, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8529951Abstract: Disclosed are elastogenic cues that can be utilized to encourage growth and development of elastin-containing cellular constructs. The elastogenic cues include hyaluronan fragments and oligomers, optionally in conjunction with growth factors and/or a source of copper ions. The elastogenic cues can up-regulate elastin matrix synthesis and by vascular smooth muscle cells. In addition to encouraging synthesis of elastin in a cellular matrix and organization into elastic fibers, the elastogenic cues can also stabilize the formed ECM matrix through suppression of elastin-laminin receptor (ELR). In addition, the elastogenic cues can inhibit cell hyper-proliferation (e.g., hyperplasia) common in inflammatory vascular disease.Type: GrantFiled: February 20, 2008Date of Patent: September 10, 2013Inventors: Anand Ramamurthi, Chandrasekhar Kothapalli, Binata Joddar
-
Patent number: 8529954Abstract: The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.Type: GrantFiled: November 10, 2009Date of Patent: September 10, 2013Assignee: Debregeas et Associes PharmaInventors: Christophe Lebon, Pascal Suplie
-
Publication number: 20130230595Abstract: Provided herein is a method of transfecting a brain cell of a subject with a polynucleotide comprising systemically administering to the subject a composition comprising a micelle having a hydrophobic superparamagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising the polynucleotide, wherein the subject has a mild traumatic brain injury.Type: ApplicationFiled: February 22, 2013Publication date: September 5, 2013Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Mahasweta Das, Chunyan Wang
-
Patent number: 8524195Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.Type: GrantFiled: December 29, 2010Date of Patent: September 3, 2013Assignee: Korea Basic Science InstituteInventors: Chulhyun Lee, Sung Lan Jeon, Min Kyung Chae, Jee-Hyun Cho, Eun Ju Jang
-
Publication number: 20130224304Abstract: An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent.Type: ApplicationFiled: April 5, 2013Publication date: August 29, 2013Applicant: Nordic Naturals, Inc.Inventor: Nordic Naturals, Inc.
-
Patent number: 8501231Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.Type: GrantFiled: June 19, 2012Date of Patent: August 6, 2013Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
-
Patent number: 8501236Abstract: A method for producing a tableting additive, which method comprises providing a spray dried tableting additive in particulate form which particles at leas partially consist of amorphous additive material and at least partially of crystalline additive material; and crystallising the amorphous additive material by subjecting the particles for a short time and under agitation to a temperature between 30 and 100° C. at a relative humidity between 60 and 25%. More in particular, the relationship between relative humidity and temperature is defined by the formula: % relative humidity=218-47*Ln(T(° C.)), wherein T(° C.) is the temperature to which the particles are subjected.Type: GrantFiled: February 29, 2012Date of Patent: August 6, 2013Assignee: Campina B.V.Inventors: Klaas Daniel Kussendrager, Henricus Alphonsus Maria Van Den Biggelaar
-
Publication number: 20130195767Abstract: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.Type: ApplicationFiled: May 26, 2011Publication date: August 1, 2013Inventors: Ralph Weissleder, Hakho Lee, Tae-Jong Yoon
-
Patent number: 8496969Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability.Type: GrantFiled: December 15, 2009Date of Patent: July 30, 2013Assignee: McNeil-PPC, Inc.Inventors: David Wynn, Nick Parikh
-
Patent number: 8497229Abstract: A granular agrochemical composition is disclosed including a granular core material having a water soluble portion with a first coating layer applied on the surface of the core material and a second coating layer applied on the surface of the first coating layer. The first coating layer includes a wax composition having a biologically active ingredient incorporated therein and the second coating layer includes a polymeric composition. The granular agrochemical composition exhibits a controlled rate of release of the biologically active ingredient therefrom over a period greater than about 30 days from the date of initial exposure of the granular composition to moisture whereby essentially all of the biologically active ingredient incorporated in the wax material of the first coating layer is released from the granular composition before the water soluble portion of the granular core material is released from the granular composition.Type: GrantFiled: January 18, 2011Date of Patent: July 30, 2013Assignee: Everris International B.V.Inventors: Lonneke Jacoba van Boxtel-Verhoeven, Johannes Gijsbertus Antonius Terlingen, Petra Leonarda Hendrica Lunde-Vannuys
-
Publication number: 20130189367Abstract: Nanoparticle having a coating comprising a polyethylenimine and a chitosan-polyethylene oxide oligomer copolymer, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and fluorescent agent.Type: ApplicationFiled: July 30, 2012Publication date: July 25, 2013Applicant: University of Washington through its Center for CommercializationInventors: Miqin Zhang, Hyejung Mok
-
Publication number: 20130189368Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.Type: ApplicationFiled: June 1, 2011Publication date: July 25, 2013Applicant: UNIVERSIDADE FEDERAL DE OURO PRETOInventors: Vanessa Carla Furtado Mosqueira, Raquel Silva Araújo, Humberto de Mello Brandão
-
Publication number: 20130189366Abstract: Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed.Type: ApplicationFiled: January 24, 2013Publication date: July 25, 2013Applicants: Brown University, The United States Government as Represented by the Department of Veterans AffairsInventors: The United States Government as Represented by the Department of Veterans Affairs, Brown University
-
Patent number: 8481070Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: GrantFiled: September 30, 2009Date of Patent: July 9, 2013Assignee: Archimedes Development LimitedInventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
-
Publication number: 20130156858Abstract: A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines.Type: ApplicationFiled: May 30, 2011Publication date: June 20, 2013Applicant: RPH Pharmaceuticals ABInventors: Per Wikström, Tobias Bramer, Lilyan Yachoh
-
Publication number: 20130156859Abstract: An immunogenic composition includes as effective ingredients: an immunogenic micro-particle composed of an antigen-adjuvant microparticle complex wherein an antigen(s) is/are encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydro-phobic segment(s) is/are poly(hydroxy acid); and a surfactant encapsulated in the immunogenic microparticle.Type: ApplicationFiled: August 25, 2011Publication date: June 20, 2013Applicant: Toray Industries, IncInventors: Yoichiro Koshi, Reiji Nishio, Yoshinori Kakizawa
-
Publication number: 20130149385Abstract: A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder.Type: ApplicationFiled: December 6, 2012Publication date: June 13, 2013Inventor: Shaker A. Mousa
-
Publication number: 20130129829Abstract: In accordance with certain embodiments of the present disclosure, a method for intracellular delivery of small molecules is provided. The method includes encapsulation of small molecules in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule and allowing the small molecules to be suck into or diffuse into the nanocapsule. The nanocapsule is delivered into a cell by increasing the temperature of the nanocapsule. The small molecules are released from the nanocapsule into the cell in a controllable manner by cooling and heating treatments.Type: ApplicationFiled: November 26, 2012Publication date: May 23, 2013Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: University of South Carolina
-
Publication number: 20130129810Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.Type: ApplicationFiled: April 12, 2011Publication date: May 23, 2013Applicants: Tel Hashomer Medical Research Infrastructure and Services Ltd., RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Jonathan Leor, Tamar Ben-Mordechai, Shimrit Adutler-Lieber, Rimona Margalit, Inbar Elron-Gross, Yifat Glucksam-Galnoy
-
Publication number: 20130129816Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.Type: ApplicationFiled: January 9, 2013Publication date: May 23, 2013Applicant: Abbott Cardiovascular Systems Inc.Inventor: Abbott Cardiovascular Systems Inc.
-
Patent number: 8445012Abstract: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.Type: GrantFiled: January 13, 2012Date of Patent: May 21, 2013Assignee: Boston Scientific Scimed, Inc.Inventors: John O'Gara, Sonali Puri
-
Publication number: 20130121929Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicant: AMAG Pharmaceuticals, Inc.Inventor: AMAG Pharmaceuticals, Inc.
-
Publication number: 20130122070Abstract: The invention provides a benefit agent delivery particle having an average diameter of less than 50 micron comprising; at least one shell formed by a step-growth polymerisation reaction, preferably involving an isocyanate monomer, more preferably a urethane and/or a urea, interior said shell, at least one region formed by chain-growth polymerisation reaction (preferably a free-radical polymerisation) which does not involve an isocyanate, c) optionally, a benefit agent interior to said shell, and/or a deposition aid exterior to said shell. The invention further provides a process for the preparation of such particles wherein the shell is formed prior to the chain-growth polymerisation of the at least one region interior of the shell, preferably be forming the shell at a temperature at which the chain-growth reaction is inhibited.Type: ApplicationFiled: July 11, 2011Publication date: May 16, 2013Inventors: Stuart Anthony Barnett, Craig Warren Jones, Adam John Limer, James Merrington, Jeremy Nicholas Winter
-
Publication number: 20130122100Abstract: Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.Type: ApplicationFiled: April 15, 2011Publication date: May 16, 2013Applicant: THE WASHINGTON UNIVERSITYInventors: Gregory M. Lanza, Dipanjan Pan
-
Publication number: 20130115297Abstract: A stable, durable granule for feed compositions has a core, at least one active agent; and at least one coating. The active agent of the granule retains at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more of a) a feed pelleting process, b) a steam-heated feed pretreatment process, c) storage, d) storage as an ingredient in an unpelleted mixture, and e) storage as an ingredient in a feed base mix or a feed premix comprising at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds which result in an acidic or a basic feed base mix or feed premix.Type: ApplicationFiled: September 25, 2012Publication date: May 9, 2013Applicant: DANISCO US INC.Inventor: Danisco US Inc.
-
Publication number: 20130115286Abstract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.Type: ApplicationFiled: July 13, 2011Publication date: May 9, 2013Inventors: Mario Brufani, Bianca Maria Lagrasta, Rolando Marzella, Ilaria Medici, Silvio Silvestri
-
Patent number: 8431221Abstract: Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein. The core particles have a diameter between about 300 nm and about 4000 nm, more particularly between about 300 nm and about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, are substantially spherical in shape, and have a substantially smooth surface.Type: GrantFiled: October 26, 2010Date of Patent: April 30, 2013Assignee: Captivate Pharmaceuticals, LLCInventors: Steve J. D. Bell, Tulin Morcol, Qing He
-
Publication number: 20130101673Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: ApplicationFiled: October 24, 2012Publication date: April 25, 2013Inventor: Mark D. Borden
-
Patent number: 8426451Abstract: An oral solid preparation including a base compound and a powdery or granular additive colored with a colorant and a method of manufacturing an oral solid preparation including the steps of: coloring an additive with a colorant, mixing the resultant additive with a base compound, and tableting the mixture.Type: GrantFiled: April 25, 2008Date of Patent: April 23, 2013Assignee: NIPRO CorporationInventors: Junichi Yokoe, Keisuke Nakajo, Naohisa Katayama, Toshiya Kai
-
Publication number: 20130095187Abstract: The present invention relates to a composition for nucleic acid delivery and a method for preparing the same, more particularly to a composition for nucleic acid delivery having excellent stability in the body environment and excellent intracellular delivery efficiency of nucleic acid, and enabling target directed delivery of nucleic acid, and a method for preparing the same.Type: ApplicationFiled: March 27, 2012Publication date: April 18, 2013Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sei Kwang HAHN, Min-Young Lee, Kitae Park, Ku Su Kim, Hwiwon Lee
-
Publication number: 20130095186Abstract: The present invention relates to a temperature-sensitive carrier for carrying a physiologically active substance and a preparation method thereof. Specifically, the temperature-sensitive carrier according to the present invention comprises an amphiphilic biodegradable block copolymer containing polysaccharide or polysaccharide and succinic anhydride as a hydrophilic block and polylactide as a non-ionic block. A hydrophilic polymer-polylactide copolymer according to the present invention forms a stable complex with a physiologically active substance such as protein, polynucleotide and the like in vivo via ionic bonding and temperature-sensitive hydrophobic bonding. Therefore, a copolymer according to the present invention can facilitate in vivo delivery of a physiologically active substance and used as an in vivo drug delivery system.Type: ApplicationFiled: June 29, 2011Publication date: April 18, 2013Inventors: Kun Na, Young Seok Jung
-
Publication number: 20130095032Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.Type: ApplicationFiled: September 27, 2012Publication date: April 18, 2013Applicant: TEL-AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P.Inventor: TEL-AVIV UNIVERSITY FUTURE TECHNOLOGY
-
Publication number: 20130089615Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.Type: ApplicationFiled: September 17, 2012Publication date: April 11, 2013Applicant: NANOCARE TECHNOLOGIES, INC.Inventor: NanoCare Technologies, Inc.
-
Publication number: 20130089599Abstract: This invention relates to a method to provide immediate, direct and controlled time release of an effective amount of therapeutics to a wound site for a prolonged period. The pharmaceutical formulation comprising a plurality of nanoparticles, said nanoparticles encapsulating a therapeutically effective amount of one or more antibacterial agents, and an application of the formulation to an implant before surgery provide for extended release of said antibacterial agents.Type: ApplicationFiled: June 10, 2012Publication date: April 11, 2013Applicant: The United States of America as Represented by the Secretary of the NavyInventors: Mauris N. DeSilva, Karen O'Connor, Amer Tiba
-
Publication number: 20130084317Abstract: The invention provides a process for producing a low calorie composite sweetener as a sugar alternative. The invention further provides a low calorie composite sweetener that can be used in many products. The low calorie composite sweetener is useful as non-caloric sweeteners in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike.Type: ApplicationFiled: November 23, 2012Publication date: April 4, 2013Applicant: PureCircle Sdn BhdInventors: Avetik MARKOSYAN, Siddhartha Purkayastha
-
Publication number: 20130084340Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Publication number: 20130078309Abstract: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: TAIHO PHARMACEUTICAL CO., LTD.